AFF1 is an inclusion eligibility criterion in 8 clinical trials for secondary myelofibrosis, of which 8 are open and 0 are closed. Of the trials that contain AFF1 status and secondary myelofibrosis as inclusion criteria, 2 are phase 1 (2 open), 5 are phase 2 (5 open), and 1 is phase 2/phase 3 (1 open) [3].

ELL is an inclusion eligibility criterion in 8 clinical trials for secondary myelofibrosis, of which 8 are open and 0 are closed. Of the trials that contain ELL status and secondary myelofibrosis as inclusion criteria, 2 are phase 1 (2 open), 5 are phase 2 (5 open), and 1 is phase 2/phase 3 (1 open) [3].

KMT2A is an inclusion eligibility criterion in 9 clinical trials for secondary myelofibrosis, of which 8 are open and 1 is closed. Of the trials that contain KMT2A status and secondary myelofibrosis as inclusion criteria, 2 are phase 1 (2 open), 6 are phase 2 (5 open), and 1 is phase 2/phase 3 (1 open) [3].

MECOM is an inclusion eligibility criterion in 9 clinical trials for secondary myelofibrosis, of which 8 are open and 1 is closed. Of the trials that contain MECOM status and secondary myelofibrosis as inclusion criteria, 2 are phase 1 (2 open), 6 are phase 2 (5 open), and 1 is phase 2/phase 3 (1 open) [3].

MLLT1 is an inclusion eligibility criterion in 8 clinical trials for secondary myelofibrosis, of which 8 are open and 0 are closed. Of the trials that contain MLLT1 status and secondary myelofibrosis as inclusion criteria, 2 are phase 1 (2 open), 5 are phase 2 (5 open), and 1 is phase 2/phase 3 (1 open) [3].

MLLT10 is an inclusion eligibility criterion in 8 clinical trials for secondary myelofibrosis, of which 8 are open and 0 are closed. Of the trials that contain MLLT10 status and secondary myelofibrosis as inclusion criteria, 2 are phase 1 (2 open), 5 are phase 2 (5 open), and 1 is phase 2/phase 3 (1 open) [3].

MLLT3 is an inclusion eligibility criterion in 8 clinical trials for secondary myelofibrosis, of which 8 are open and 0 are closed. Of the trials that contain MLLT3 status and secondary myelofibrosis as inclusion criteria, 2 are phase 1 (2 open), 5 are phase 2 (5 open), and 1 is phase 2/phase 3 (1 open) [3].

MLLT4 is an inclusion eligibility criterion in 8 clinical trials for secondary myelofibrosis, of which 8 are open and 0 are closed. Of the trials that contain MLLT4 status and secondary myelofibrosis as inclusion criteria, 2 are phase 1 (2 open), 5 are phase 2 (5 open), and 1 is phase 2/phase 3 (1 open) [3].

NRIP3 is an inclusion eligibility criterion in 8 clinical trials for secondary myelofibrosis, of which 8 are open and 0 are closed. Of the trials that contain NRIP3 status and secondary myelofibrosis as inclusion criteria, 2 are phase 1 (2 open), 5 are phase 2 (5 open), and 1 is phase 2/phase 3 (1 open) [3].

RPN1 is an inclusion eligibility criterion in 9 clinical trials for secondary myelofibrosis, of which 8 are open and 1 is closed. Of the trials that contain RPN1 status and secondary myelofibrosis as inclusion criteria, 2 are phase 1 (2 open), 6 are phase 2 (5 open), and 1 is phase 2/phase 3 (1 open) [3].